Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 7, 2021 Expiration: October 6, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
Helsinn Healthcare SA
Merck Sharp & Dohme Corp.
Julie Brahmer, MD, MSc
person default
Jarushka Naidoo, MB BCH BAO, MHS

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal first-line immune checkpoint inhibitor and chemotherapy combinations for patients with advanced or metastatic NSCLC

  • Evaluate the available clinical data on biomarkers of response to immune checkpoint inhibitor–based therapy in NSCLC

  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy and in those who are ineligible for surgery or chemoradiation therapy

  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of clinical care strategies for NSCLC

  • Address factors that have the potential to reduce efficacy of ICI therapy in individual patients with NSCLC

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Julie Brahmer, MD, MSc

Professor of Oncology
Director, 
Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Julie Brahmer, MD, MSc, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Lilly, Merck, Regeneron, and Sanofi; funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics, and Revolution Medicines; and fees for non-CME/CE services from GlaxoSmithKline, Janssen, and Sanofi.
Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS, has disclosed that she has received consulting fees from AstraZeneca, Daiichi Sankyo, Merck, Pfizer, Roche/Genentech, and Takeda and funds for research support from AstraZeneca and Merck.

Staff

Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Shara Pantry, PhD
Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with non-small-cell lung cancer.

Goal

The goal of this program is to improve the knowledge and competence of learners in immuno-oncology for the treatment of non-small-cell lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 07, 2021, through October 06, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Understanding the Evolving Immuno-Oncology Treatment Paradigm in Non-Small-Cell Lung Cancer
  • CME

Loading...

Watch this on-demand webcast of a live CCO webinar where lung cancer experts discuss the latest advances in immunotherapy for the management of NSCLC across the disease spectrum, including in special populations and new data from WCLC 2021.

Julie Brahmer, MD, MSc
person default
Jarushka Naidoo, MB BCH BAO, MHS
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: October 7, 2021 Expiration: October 6, 2022

Related Content

In this commentary from Clinical Care Options (CCO), Dr. David Planchard provides an overview of the status of EGFR TKI combination therapy for newly diagnosed EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021

Downloadable slideset on the use of neoadjuvant immunotherapy in resectable early-stage lung cancer, from Clinical Care Options (CCO)

Released: December 1, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on EGFR Exon 20–Altered NSCLC.

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Released: December 1, 2021

PDF transcript of a podcast where lung cancer experts answer clinical questions on evolving immunotherapy strategies for NSCLC, from Clinical Care Options (CCO)

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: December 1, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
Helsinn Healthcare SA
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue